Ultragenyx Pharmaceutical Inc. Stock News

NOVATO, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for seri

Ultragenyx (RARE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

NOVATO, Calif., July 20, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for r

Gainers Applied Blockchain, Inc. (NASDAQ: APLD) shares climbed 100% to close at $2.12 on Tuesday after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings an

Earlier today, Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) released updated interim GTX-102 data, including Day 128 assessments from 9 patients.  The Overall CGI-C-AS score improved by 1 point in

U.S. stocks extended gains toward the end of trading, with the Nasdaq Composite gaining around 3% on Tuesday. The Dow traded up 2.23% to 31,764.51 while the NASDAQ rose 2.99% to 11,699.21. The S&P al

Shareholders aren't happy with the biotech's decision to acquire an early-stage asset for Angelman syndrome.

U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 500 points on Tuesday. The Dow traded up 1.64% to 31,581.59while the NASDAQ rose 2.11% to 11,599.41. The S&P also ro

Gainers Applied Blockchain, Inc. (NASDAQ: APLD) jumped 50.1% to $1.5907 after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and raised its Q4 revenue f

Earlier today, Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) released updated interim GTX-102 data, including Day 128 assessments from 9 patients.  The Overall CGI-C-AS score improved by 1 point in

Ultragenyx (RARE) and GeneTx Biotherapeutics provide an update and positive interim data from the phase I/II study on GTX-102 for treating patients with Angelman syndrome.

U.S. stocks traded higher this morning, with the Dow Jones gaining more than 350 points on Tuesday. Following the market opening Tuesday, the Dow traded up 1.15% to 31,429.04 while the NASDAQ rose 1.1

Shareholders aren't happy with the biotech's decision to acquire an early-stage asset for Angelman syndrome.

Ultragenyx (RARE) and GeneTx Biotherapeutics provide an update and positive interim data from the phase I/II study on GTX-102 for treating patients with Angelman syndrome.

Ultragenyx (RARE) sells 30% of the royalty interest receivable on future North America sales of Crysvita for $500 million. The total payments are capped at 1.45 times the purchase price.